TScan Therapeutics (NASDAQ:TCRX – Get Free Report) and Altimmune (NASDAQ:ALT – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.
Analyst Ratings
This is a breakdown of recent ratings for TScan Therapeutics and Altimmune, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TScan Therapeutics | 1 | 5 | 2 | 0 | 2.12 |
| Altimmune | 1 | 1 | 8 | 0 | 2.70 |
TScan Therapeutics currently has a consensus target price of $2.67, indicating a potential upside of 1,240.71%. Altimmune has a consensus target price of $14.33, indicating a potential upside of 582.54%. Given TScan Therapeutics’ higher possible upside, research analysts clearly believe TScan Therapeutics is more favorable than Altimmune.
Profitability
This table compares TScan Therapeutics and Altimmune’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TScan Therapeutics | -1,655.35% | -108.72% | -54.47% |
| Altimmune | N/A | -31.41% | -26.96% |
Risk and Volatility
TScan Therapeutics has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.06, meaning that its stock price is 94% less volatile than the S&P 500.
Insider & Institutional Ownership
82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 78.0% of Altimmune shares are owned by institutional investors. 6.2% of TScan Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares TScan Therapeutics and Altimmune”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TScan Therapeutics | $7.11 million | 1.90 | -$129.77 million | ($0.91) | -0.22 |
| Altimmune | $40,000.00 | 10,212.30 | -$88.09 million | ($0.78) | -2.69 |
Altimmune has lower revenue, but higher earnings than TScan Therapeutics. Altimmune is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Altimmune beats TScan Therapeutics on 8 of the 14 factors compared between the two stocks.
About TScan Therapeutics
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
About Altimmune
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
